Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Endocrine 1CNS 1

Conditions

Breast Neoplasms 629Prostatic Neoplasms 371Neoplasms 307Carcinoma, Non-Small-Cell Lung 215Lung Neoplasms 204Colorectal Neoplasms 176Multiple Myeloma 144Pancreatic Neoplasms 136Leukemia, Myeloid, Acute 128Neoplasm Metastasis 124Brain Neoplasms 117Melanoma 116Ovarian Neoplasms 103Carcinoma, Hepatocellular 102Precursor Cell Lymphoblastic Leukemia-Lymphoma 100Glioblastoma 99Uterine Cervical Neoplasms 97Head and Neck Neoplasms 95Squamous Cell Carcinoma of Head and Neck 94Colonic Neoplasms 81Stomach Neoplasms 80Recurrence 80Rectal Neoplasms 80Urinary Bladder Neoplasms 77Sarcoma 77Triple Negative Breast Neoplasms 75Carcinoma, Renal Cell 75Lymphoma 71Leukemia, Lymphocytic, Chronic, B-Cell 68Lymphoma, Non-Hodgkin 67

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × OTHER × Vascular Neoplasms × Clear all
NCT02721732 2026-01-29

Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
157 enrolled 26 charts
CNSEndocrineGenitourinary

Adrenal Cortex Neoplasms, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms, Unknown Primary, Paraganglioma, Penile Neoplasms, Pheochromocytoma, Carcinoma, Small Cell, Vascular Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡